From: "Joesph Feldman" <iyinspfozvxg@dreamer.com.tw>
To: <paliourg@iit.demokritos.gr>
Subject: Are you a savvy pinksheet player? 
Date: Fri, 19 Nov 2004 05:02:19 +0300
MIME-Version: 1.0
Content-Type: text/html;
	charset="iso-8859-7"
Content-Transfer-Encoding: quoted-printable
X-Priority: 3
X-MSMail-Priority: Normal
X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2900.2527

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<META HTTP-EQUIV=3D"Content-Type" CONTENT=3D"text/html; =
charset=3Diso-8859-7">
<META NAME=3D"Generator" CONTENT=3D"MS Exchange Server version =
6.5.7036.0">
<TITLE>Are you a savvy pinksheet player? </TITLE>
</HEAD>
<BODY>
<!-- Converted from text/plain format -->

<P><FONT SIZE=3D2>Earnings Announcement At The Close Thursday, November =
18,2004<BR>
Genex Pharmaceutical, Inc. (OTCBB: GENX)<BR>
Current Price: 1.20<BR>
<BR>
Net In come Three Months Ended September 30, 2004 Soars 215% to 387,296 =
Compared to 122,973 for the Same Period Last Year. (Source: 10Q Filed =
11.17.04)<BR>
<BR>
Now That the In come is Soaring, Will the Stock Price do the Same??<BR>
<BR>
Press Release Source: Genex Pharmaceutical, Inc.<BR>
<BR>
<BR>
Genex Pharmaceutical Announces In crease of 215% in Net In come for =
Record Third Quarter<BR>
Thursday November 18, 4:45 pm ET<BR>
<BR>
<BR>
TIANJIN, China. BUSINESS WIRE. Nov. 18, 2004. Genex Pharmaceutical =
(OTCBB: GENX) announced financial results for the third quarter ending =
September 30, 2004. The following are some of the highlights in its =
quarterly filing with the SEC:<BR>
<BR>
215% in crease in Net In come for Q3 2004 compared to Q3 2003;<BR>
103% in crease in Revenue for Q3 2004 compared to Q3 2003;<BR>
107% in crease in Gross Prof it for Q3 2004 compared to Q3 2003;<BR>
<BR>
Revenue<BR>
<BR>
For the three month period ended September 30, 2004 as compared to the =
three month period ended September 30, 2003, we generated net revenues =
of 741,353 and 365,203, respectively, reflecting an in crease of 376,150 =
or 103%. The in crease in revenues was primarily attributable to the =
commercialization of our main product, Reconstituted Bone Xenograft, as =
well as in creased marketing efforts, which resulted in in creases in =
our customer base and related volume of recurring and new customer =
sales. For the nine month period ended September 30, 2004 as compared to =
the period ended September 30, 2003, we generated net revenues of =
1,598,770 and 463,966, respectively, reflecting an in crease of =
1,134,804 or 245%.<BR>
<BR>
Gross prof it<BR>
<BR>
We achieved a gross prof it of 665,260 for the three months ended =
September 30, 2004, an in crease of 344,583 or 107%, compared to 320,677 =
for the three months ended September 30, 2003. Gross margin, as a =
percentage of revenues, in creased from 88% for the three months ended =
September 30, 2003, to 90% for the three months ended September 30, =
2004. The in crease in gross margin was primarily attributable to =
commercialization of our main product, Reconstituted Bone Xenograft, and =
increased sales of products. We achieved a gross prof it of 1,423,300 =
for the nine months ended September 30, 2004, an in crease of 1,021,986 =
or 255%, compared to 401,314 for the period ended September 30, 2003. =
Gross margin, as a percentage of revenues, in creased from 86% for the =
nine months ended September 30, 2003, to 89% for the period ended =
September 30, 2004. The in crease in gross margin was primarily =
attributable to commercialization of our main product, Reconstituted =
Bone Xenograft, and in creased sales of products.<BR>
<BR>
Net In come<BR>
<BR>
Our net in come was 387,296 for the three months ended September 30, =
2004, an in crease of 264,323 or 215%, compared to 122,973 for the three =
months ended September 30, 2003. The in crease is attributed to the =
substantial growth in the demand for our products throughout China and =
continued development and implementation of our business during 2004. =
Our net in come was 605,891 for the nine months ended September 30, =
2004,an in crease of 506,847 or 512%, compared to 99,044 for the period =
ended September 30,2003. The in crease is attributed to the substantial =
growth in the demand for our products throughout China and continued =
development and implementation of our business during 2004.<BR>
<BR>
About Genex Pharmaceutical, Inc.<BR>
<BR>
Genex Pharmaceutical, Inc. is a biomedical technology company with =
distinctive proprietary technology for an orthopedic device that treats =
bone-related injuries. Headquartered in Tianjin, China, the Company =
manufactures and distributes Reconstituted Bone Xenograft (RBX), to 400 =
hospitals in 22 provinces throughout mainland China. RBX is approved by =
the State Food and Drug Administration (SFDA) in China (the Chinese =
government agency that regulates drugs and medical devices). RBX offers =
a modern alternative to traditional methods of treating orthopedic =
injuries.<BR>
<BR>
<BR>
Information within this e mail contains future looking statements within =
the meaning of Section 27A of the Securities Act of 1933 and Section 21B =
of the Securities Exchange Act of 1934. Any statements that express or =
involve discussions with respect to predictions, expectations, beliefs, =
plans, projections, objectives, goals, assumptions or future events or =
performance are not statements of historical fact and may be future =
looking statements. Future looking statements are based on expectations, =
estimates and projections at the time the statements are made that =
involve a number of risks and uncertainties which could cause actual =
results or events to differ materially from those presently anticipated. =
Future looking statements in this action may be identified through the =
use of words such as projects , foresee, expects, will, anticipates, =
estimates, believes, understands or that by statements indicating =
certain actions may, could, or might occur. As with many micro-cap =
stocks, today's company has additional risk factors worth noting. Those =
factors include: a limited operating history: the company advancing cash =
to related parties and a shareholder on an unsecured basis: one vendor, =
a related party through a majority stockholder, supplies ninety-seven =
percent of the company's raw materials: reliance on two customers for =
over fifty percent of their business and numerous related party =
transactions and the need to raise capital. Other factors include, but =
are not limited to, expected market demand for the Company's services, =
fluctuations in pricing for products distributed by the Company and =
services offered by competitors, exchange rate risks, as well as general =
conditions of the medical device marketplace. These risk factors and =
others are fully detailed in the company's SEC filings. We urge you to =
read them before you invest. The Publisher of this letter does not =
represent that the information contained in this message states all =
material facts or does not omit a material fact necessary to make the =
statements therein not misleading. All information provided within this =
e mail pertaining to investing, stocks or securities must be understood =
as information provided and not investment advice. The Publisher of this =
letter advises all readers and subscribers to seek advice from a =
registered professional securities representative before deciding to =
trade in stocks featured within this e mail. None of the material within =
this report shall be construed as any kind of investment advice or =
solicitation. Many of these companies are on the verge of bankruptcy. =
You can lose all your money by investing in this stock. The Publisher of =
this letter is not a registered investment expert. Subscribers should =
not view information herein as legal, tax, accounting or investment =
advice. Any reference to past performance(s) of companies are specially =
selected to be referenced based on the favorable performance of these =
companies. You would need perfect timing to acheive the results in the =
examples given. There can be no assurance of that happening. Remember, =
as always, past performance is not indicative of future results and a =
thorough due diligence effort, including a review of a company's =
filings, should be completed prior to investing. In compliance with the =
Securities Act of 1933, Section17(b),The Publisher of this letter =
discloses the receipt of fourty four thousand dollars from a third =
party, not an officer, director or affiliate shareholder for the =
circulation of this report. Be aware of an inherent conflict of interest =
resulting from such compensation due to the fact that this is a paid =
report and is not without bias. The party that paid us has a position in =
the stock they will sell at any time without notice. This could have a =
negative impact on the price of the stock. All factual information in =
this report was gathered from public sources, including but not limited =
to Company Websites, SEC Filings and Company Press Releases. The =
Publisher of this letter believes this information to be reliable but =
can make no assurance as to its accuracy or completeness. Use of the =
material within this e mail constitutes your acceptance of these =
terms.<BR>
</FONT>
</P>

</BODY>
</HTML>
